Aim of the project is to evaluate the therapeutic potential of a new synthetic molecule, called BU10119, for the treatment of alcohol addiction. This molecule acts as a NOP agonist and MOP antagonist.

NOP-AUD
-
Beneficiario
Scripps Research Institute
National Institutes of Health (NIH)
450.000 €
450.000 €